Erin A McClure1, Nathaniel L Baker2, Susan C Sonne3, Udi E Ghitza4, Rachel L Tomko3, LaTrice Montgomery5, Shanna Babalonis6, Garth E Terry7, Kevin M Gray3. 1. Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States. Electronic address: mccluree@musc.edu. 2. Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States. 3. Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States. 4. Center for Clinical Trials Network, National Institute on Drug Abuse, Bethesda, MD, United States. 5. Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, United States. 6. Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, United States. 7. Northwest Network Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, United States; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States.
Abstract
BACKGROUND: It is common for cannabis users to also use tobacco. While data suggest that tobacco users have more difficulty achieving cannabis cessation, secondary analyses of clinical trial data sets may provide insight into the moderating variables contributing to this relationship, as well as changes in tobacco use during cannabis treatment. Those were the aims of this secondary analysis. METHODS: The parent study was a multi-site trial of N-acetylcysteine for cannabis dependence conducted within the National Drug Abuse Treatment Clinical Trials Network. Participants were treatment-seeking adults (ages 18-50) who met criteria for cannabis dependence (N = 302). For cigarette smokers (n = 117), tobacco use was assessed via timeline follow-back and nicotine dependence was assessed via the Fagerström Test for Nicotine Dependence (FTND). Outcome measures included: 1) changes in tobacco use based on treatment assignment, nicotine dependence, and concurrent cannabis reduction/abstinence, and 2) independent associations between nicotine dependence and cannabis abstinence. RESULTS: Cigarette smokers accounted for 39% of the sample (117/302), with a median FTND score of 3.0 (10-point scale). Among those with lower baseline nicotine dependence scores, cigarette smoking was reduced in the active treatment group compared to placebo. Those with moderate/high levels of nicotine dependence showed slight increases in smoking following active treatment. Nicotine dependence did not affect cannabis cessation. CONCLUSIONS: Cigarette smoking during cannabis treatment was affected, but depended on baseline nicotine dependence severity, though dependence levels did not impact cannabis abstinence. Interventions that address both tobacco and cannabis are needed, especially due to an increasing prevalence of cannabis use.
BACKGROUND: It is common for cannabis users to also use tobacco. While data suggest that tobacco users have more difficulty achieving cannabis cessation, secondary analyses of clinical trial data sets may provide insight into the moderating variables contributing to this relationship, as well as changes in tobacco use during cannabis treatment. Those were the aims of this secondary analysis. METHODS: The parent study was a multi-site trial of N-acetylcysteine for cannabis dependence conducted within the National Drug Abuse Treatment Clinical Trials Network. Participants were treatment-seeking adults (ages 18-50) who met criteria for cannabis dependence (N = 302). For cigarette smokers (n = 117), tobacco use was assessed via timeline follow-back and nicotine dependence was assessed via the Fagerström Test for Nicotine Dependence (FTND). Outcome measures included: 1) changes in tobacco use based on treatment assignment, nicotine dependence, and concurrent cannabis reduction/abstinence, and 2) independent associations between nicotine dependence and cannabis abstinence. RESULTS: Cigarette smokers accounted for 39% of the sample (117/302), with a median FTND score of 3.0 (10-point scale). Among those with lower baseline nicotine dependence scores, cigarette smoking was reduced in the active treatment group compared to placebo. Those with moderate/high levels of nicotine dependence showed slight increases in smoking following active treatment. Nicotine dependence did not affect cannabis cessation. CONCLUSIONS: Cigarette smoking during cannabis treatment was affected, but depended on baseline nicotine dependence severity, though dependence levels did not impact cannabis abstinence. Interventions that address both tobacco and cannabis are needed, especially due to an increasing prevalence of cannabis use.
Authors: Kimber P Richter; Haroshena Kaur; Ken Resnicow; Niaman Nazir; Michael C Mosier; Jasjit S Ahluwalia Journal: Subst Abus Date: 2004-06 Impact factor: 3.716
Authors: Gillian L Schauer; Carla J Berg; Michelle C Kegler; Dennis M Donovan; Michael Windle Journal: Nicotine Tob Res Date: 2015-05-25 Impact factor: 4.244
Authors: Ahmed Jamal; Brian A King; Linda J Neff; Jennifer Whitmill; Stephen D Babb; Corinne M Graffunder Journal: MMWR Morb Mortal Wkly Rep Date: 2016-11-11 Impact factor: 17.586
Authors: Kenneth H Levin; Marc L Copersino; Stephen J Heishman; Fang Liu; Deanna L Kelly; Douglas L Boggs; David A Gorelick Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Arpana Agrawal; Michael T Lynskey; Pamela A F Madden; Michele L Pergadia; Kathleen K Bucholz; Andrew C Heath Journal: Drug Alcohol Depend Date: 2008-12-09 Impact factor: 4.492
Authors: Erica N Peters; Robert P Schwartz; Shuai Wang; Kevin E O'Grady; Carlos Blanco Journal: Drug Alcohol Depend Date: 2013-10-14 Impact factor: 4.492
Authors: Erin A McClure; Rachel L Tomko; Claudia A Salazar; Saima A Akbar; Lindsay M Squeglia; Evan Herrmann; Matthew J Carpenter; Erica N Peters Journal: Exp Clin Psychopharmacol Date: 2018-12-17 Impact factor: 3.157
Authors: Saima A Akbar; Rachel L Tomko; Claudia A Salazar; Lindsay M Squeglia; Erin A McClure Journal: Addict Behav Date: 2018-11-27 Impact factor: 3.913
Authors: Christopher J Hammond; Suchitra Krishnan-Sarin; Linda C Mayes; Marc N Potenza; Michael J Crowley Journal: Int J Ment Health Addict Date: 2020-05-15 Impact factor: 3.836
Authors: Rachel L Tomko; Nathaniel L Baker; Caitlyn O Hood; Amanda K Gilmore; Erin A McClure; Lindsay M Squeglia; Aimee L McRae-Clark; Susan C Sonne; Kevin M Gray Journal: Psychopharmacology (Berl) Date: 2019-11-11 Impact factor: 4.530
Authors: Andrew H Rogers; Justin M Shepherd; Julia D Buckner; Lorra Garey; Kara Manning; Michael F Orr; Norman B Schmidt; Michael J Zvolensky Journal: Drug Alcohol Depend Date: 2020-02-19 Impact factor: 4.492
Authors: Shannon M Rogers; Melissa B Harrell; Baojiang Chen; Andrew Springer; Alexandra Loukas; Cheryl L Perry Journal: Addict Behav Date: 2020-12-08 Impact factor: 3.913